The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PHAR | +132.61% | +43.15% | +7.43% | +23% |
| S&P | +14.29% | +86.82% | +13.3% | +88% |
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.
No news articles found for Pharming Group.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $96.87M | 29.0% |
| Gross Profit | $89.80M | 31.6% |
| Gross Margin | 92.70% | 1.8% |
| Market Cap | $993.46M | 77.5% |
| Net Income | $7.47M | 820.1% |
| EBITDA | $18.54M | 204.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $133.06M | 119.3% |
| Accounts Receivable | $43.61M | -9.5% |
| Inventory | 67.1 | 7.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $121.23M | 1.1% |
| Short Term Debt | $9.69M | 34.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 0.24% | 4.3% |
| Return On Invested Capital | 2.60% | -7.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $29.94M | 220.6% |
| Operating Free Cash Flow | $30.01M | 209.2% |
| Metric | Q3 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 1006.94 | - | |||
| Price to Book | 3.02 | 2.51 | 3.40 | 4.37 | 76.32% |
| Price to Sales | 2.31 | 1.78 | 2.15 | 2.74 | 40.28% |
| Price to Tangible Book Value | 4.30 | 3.58 | 9.68 | 10.87 | 208.14% |
| Price to Free Cash Flow TTM | 208.61 | 25.79 | 20.27 | - | |
| Enterprise Value to EBITDA | 68.35 | 196.92 | 53.25 | 51.64 | -38.92% |
| Free Cash Flow Yield | 0.5% | 3.9% | 4.9% | - | |
| Return on Equity | -5.0% | -6.3% | -3.4% | 0.4% | -105.46% |
| Total Debt | $112.31M | $119.14M | $140.55M | $130.92M | 3.02% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
